Carmell Corporation (CTCX)

2,0500 -0,0800 (-3,76%) Alla chiusura: 04:00PM EDT

Carmell Corporation

2403 Sidney Street
Suite 300
Pittsburgh, PA 15203
United States
919 313 9633
https://www.carmellcosmetics.com

Settore/i: Healthcare
Settore: Biotechnology
Impiegati a tempo pieno: 9

Figure dirigenziali chiave

Nome	Titolo	Retribuzione	Esercitate	Anno di nascita
Mr. Rajiv Sarman Shukla	Executive Chairman & CEO	292,19k	N/D	1975
Mr. Bryan J. Cassaday	Chief Financial Officer	261,7k	N/D	1969
Dr. Phil Campbell Ph.D.	Founder and Chief Scientific Officer	N/D	N/D	N/D
Dr. Lee Weiss Ph.D.	Founder	N/D	N/D	N/D
Dr. James Burgess M.D.	Founder	N/D	N/D	N/D

Gli importi risalgono al giorno 31 dicembre 2023 e i valori di compensazione riguardano l'anno fiscale che si chiude a tale data. La retribuzione include salari, bonus ecc. "Esercitate" è il valore delle opzioni esercitate durante l'anno fiscale. Valuta in USD.

Descrizione

Carmell Corporation operates as a bio-aesthetics company. The company utilizes Carmell Secretome to support skin and hair health. Its Carmell Secretome consists of growth factors and proteins extracted from allogeneic human platelets sourced from tissue banks. The company also developed a microemulsion formulation that enables delivery of lipophilic and hydrophilic ingredients without relying on the Foul Fourteen, 14 potentially harmful excipients that are commonly used by other companies to impart texture, stability, and other desirable physicochemical attributes to cosmetic products. In addition, the company is also developing a line of men's products and a line of topical haircare products. It has licensing agreement with Carnegie Mellon University to develop and commercialize biocompatible plasma-based plastics. The company was formerly known as Carmell Therapeutics Corporation and changed its name to Carmell Corporation in November 2023. Carmell Therapeutics Corporation was founded in 2008 and is headquartered in Pittsburgh, Pennsylvania.

Governance aziendale

L'ISS Governance QualityScore di Carmell Corporation al N/D è N/D. I criteri di valutazione fondamentali sono revisione: N/D; Consiglio di Amministrazione: N/D; diritti degli azionisti: N/D; retribuzione: N/D.

Punteggi di corporate governance forniti da Institutional Shareholder Services (ISS). I punteggi indicano il rango decile relativo all’indice o alla regione. Un punteggio di decile pari a 1 indica un governance risk più basso, mentre un punteggio di 10 indica un governance risk più alto.